Global Regulatory Updates on Clinical Trials (December 2025)

Several regulatory updates were issued by global health authorities in December 2025, with direct implications for sponsors and stakeholders conducting Phase I–IV clinical trials and developing drugs and biologics worldwide. Caidya’s Regulatory & Strategic Development (RSD) team has compiled a high-level summary of final and draft guidance and policy updates from the FDA (USA), EMA (European Union), NMPA (China), TGA (Australia), Health Canada, and ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) that may influence trial design, conduct, safety reporting, and oversight across regions. 

U.S. Food and Drug Administration (FDA) 

Final Updates 

• Enhancing Participation in Clinical Trials – Eligibility Criteria, Enrollment Practices, and Trial Designs (Guidance for Industry) – Final FDA guidance issued in Dec 2025 that recommends ways for sponsors to broaden clinical trial eligibility criteria and enrollment to improve participant diversity and representativeness (fda.gov). It provides strategies to include diverse demographic and non-demographic patient populations so trial results better reflect real-world patient groups  

• Sponsor Responsibilities – Safety Reporting Requirements and Safety Assessment for IND and BA/BE Studies – Final guidance (Dec 2025) detailing how sponsors and sponsor-investigators must comply with investigational new drug (IND) safety reporting rules, including when and how to submit IND safety reports and how to assess aggregate safety data (fda.gov). The guidance clarifies key terms and expectations to ensure timely, appropriate safety reporting in clinical trials. 

• Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices – Final guidance (Dec 2025) outlining clinical investigators’ obligations for safety reporting in drug and medical device trials (fda.gov). It provides recommendations to help investigators identify what adverse events or safety information must be reported to sponsors and institutional review boards (IRBs) during IND or IDE studies  

• Processes and Practices Applicable to Bioresearch Monitoring (BIMO) Inspections – Final guidance (Dec 2025) published to fulfill a congressional mandate (Food and Drug Omnibus Reform Act 2022) by describing how FDA conducts inspections of clinical trial sites (fda.gov). It covers what records and information may be required, best practices for communications between FDA and trial sponsors/investigators before and during inspections, and other expectations to improve transparency in GCP compliance inspections. 

• Policy Announcement on Real-World Evidence (RWE) in Regulatory Submissions – FDA announced (Dec 15, 2025) the removal of a major barrier to using RWE in drug and device applications (fda.gov). Specifically, new guidance for device submissions (and planned updates for drugs/biologics) will allow the FDA to consider aggregated real-world data without always requiring patient-identifiable datasets, enabling sponsors to leverage de-identified registry and electronic health record data to support clinical effectiveness and safety claims. 

Draft Updates 

(No new FDA draft guidance specific to clinical trial phases I–IV was released in December 2025. FDA’s draft guidances on clinical trial topics in late 2025 were primarily issued earlier in the year.) 

European Medicines Agency (EMA) 

Final Updates 

(No EMA guidance documents specifically focused on clinical trial design or conduct were finalized in December 2025. EMA’s efforts in this period centered on implementing the EU Clinical Trials Regulation and preparing for upcoming pharmaceutical legislation changes ema.europa.eu.) 

Draft Updates  

• Concept Paper – Revision of Guideline on Parkinson’s Disease Clinical Trials – EMA’s CHMP released a concept paper (published Dec 1, 2025) proposing to update the 2012 guideline on clinical investigation of drugs for Parkinson’s disease.  The concept paper signals planned revisions to incorporate advances in disease understanding and to address multiple parkinsonian conditions (e.g. multiple system atrophy, progressive supranuclear palsy) under a modernized trial design framework (ema.europa.eu). 

• Concept Paper – Revision of Guideline on Good Pharmacogenomic Practice – EMA issued a concept paper on Dec 8, 2025, to initiate revision of its 2018 guidance for pharmacogenomic best practices. It outlines the need to update recommendations for integrating pharmacogenomic analyses into clinical trials and drug development, reflecting new technologies and knowledge in genomic medicine. The goal is to improve how genomic data are collected and used to inform trial design and interpretation (ema.europa.eu). 

National Medical Products Administration (NMPA – China) 

Final Updates 

• Adoption of ICH GCP E6(R3) – NMPA announced (Dec 22, 2025) that the ICH E6(R3) Good Clinical Practice guideline will be applied to all drug clinical trials initiated in China on or after March 31, 2026. This harmonization step updates China’s GCP standards to the modern, risk-based E6(R3) principles, and sponsors are expected to comply with E6(R3) for any new trials starting from that date forward (cncsdr.org). 

• Oncology Guidances – Single-Arm Trials and Pan-Tumor Therapies – NMPA’s Center for Drug Evaluation (CDE) issued two significant oncology trial guidances on Dec 29–30, 2025. One guidance addresses the use of single-arm clinical trials to support regular marketing approval of anti-cancer drugs, detailing the circumstances and evidence (e.g. response rates with durable benefit) under which a single-arm trial may be acceptable for approval (news.qq.com). Another guidance—Guideline on Clinical Development of Antitumor Drugs for Pan-Tumor Indications—provides recommendations for designing trials of cancer therapies that target biomarkers across multiple tumor types (tumor-agnostic indications ). It covers rationale for a pan-tumor development program, key trial design considerations (such as patient selection by molecular marker, use of basket trial designs), companion diagnostics co-development, and special topics like pediatric subpopulations (vbdata.cn). 

• Disease-Specific Clinical Trial Guidelines – On December 30, 2025, NMPA’s CDE released a set of new technical guidelines to steer clinical development in specific therapeutic areas (news.qq.com). These included guidance on trials for eosinophilic esophagitis treatments (detailing endpoints and study design for this rare inflammatory condition), guidance on trials for HIV therapies addressing incomplete immune reconstitution (for patients whose CD4 counts don’t recover on ART, outlining trial endpoints and safety measures), and a guidance (issued as “trial implementation”) on clinical trials of targeted anti-inflammatory biologics for chronic airway diseases like severe asthma or COPD. Each of these guidances provides tailored design considerations (patient population criteria, efficacy endpoints, etc.) to ensure robust Phase II–III trials in the respective area. Additionally, a Traditional Medicine guidance was issued (trial-use) on how to collect and analyze real-world human-use experience data to support new traditional Chinese medicine drug development (news.qq.com), aiming to formalize the use of observational/historical data alongside clinical trials for such products. 

Draft Updates 

(No draft guidance documents on clinical trial phases I–IV were released for consultation by NMPA in December 2025. The agency focused on finalizing the multiple guidance documents listed above at year-end.) 

Therapeutic Goods Administration (TGA – Australia) 

Final Updates 

• Adoption of ICH E6(R3) GCP Guideline – The TGA formally adopted the ICH E6(R3) Good Clinical Practice guideline as of December 16, 2025 . This means Australia’s GCP standards for drug and biologic trials are now aligned with the latest ICH E6(R3) principles, which emphasize flexibility and risk-based trial oversight. Sponsors and ethics committees in Australia are expected to transition to the E6(R3) practices in preparation for full implementation (Australia coordinated this adoption in parallel with other regulators) (tga.gov.au). 

(TGA did not issue additional standalone guidance documents on clinical trial design or conduct in December 2025 beyond adoption of international (ICH) guidelines.) 

Draft Updates 

• Consultation on ICH GCP Annotations – In late 2025, TGA sought stakeholder feedback on its proposed national annotations and a 12-month transition plan for adopting ICH E6(R3) GCP (isctglobal.org). (This consultation occurred in October 2025, with TGA considering comments through the fall. No new draft consultations specific to clinical trials were opened in December.) 

Health Canada 

Final Updates 

• Planned Implementation of ICH E6(R3) GCP – Health Canada announced (via an Oct 17, 2025 notice to stakeholders, publicized in Q4 2025) that it will implement the ICH E6(R3) Good Clinical Practice guideline effective April 1, 2026.  A six-month transition period is provided for sponsors and researchers to train and update their procedures to the new GCP standard. This adoption of E6(R3) aligns Canada’s clinical trial oversight with the modernized international GCP framework focusing on risk-based trial management (canada.ca). 

Draft Updates 

• Draft Guidance on Decentralized Clinical Trials – Health Canada published a draft guidance for consultation on Dec 23, 2025, addressing decentralized clinical trials (DCTs). This draft guidance outlines regulatory considerations and practical strategies for conducting trials with decentralized elements in Canada, such as remote patient monitoring, virtual visits, and use of digital health technologies.. The aim is to facilitate trials that occur partially or fully outside traditional sites while ensuring compliance with Part C, Division 5 of the Food and Drug Regulations and ICH GCP requirements.. The consultation on this draft is open until Feb 21, 2026, after which Health Canada will finalize the guidance based on stakeholder feedback (canada.ca). 

(Health Canada’s other draft guidance consultations in late 2025 — such as those on clinical trial regulation modernization and summary safety report requirements — had either concluded by early December or were outside the scope of Phase I–IV trial design.)

International Council for Harmonisation (ICH) 

Final Updates 

• ICH M11 – Harmonized Clinical Trial Protocol Template – In late 2025, ICH adopted the final M11 guideline, which provides a common template and technical specification for electronic clinical trial protocols. At the November 2025 ICH Assembly meeting, regulators endorsed the M11 “Clinical Electronic Structured Harmonised Protocol (CeSHarP) Template” – a standardized format intended to simplify protocol development and review across regions (raps.org). This harmonized protocol template defines a consistent structure and content for trial protocols, facilitating efficiency and enabling use of digital protocol data exchange by sponsors and regulators. 

• New ICH Topics for Clinical Research – The ICH Assembly in November 2025 also approved new work items aimed at enhancing clinical trial methodologies. Notably, ICH members agreed to develop a guideline on incorporating patient preference studies into drug development . This forthcoming guideline (now in early draft stage) will cover the design, conduct, and analysis of studies that gather patient preferences (e.g. benefit-risk tradeoffs) to inform regulatory decisions (raps.org). By initiating this project, ICH recognizes the value of patient preference data and is moving toward globally harmonized standards on how such data should be collected and submitted alongside clinical trial evidence. 

Draft Updates 

• Draft ICH Guideline on Patient Preference Studies – Following the new topic approval, a draft guideline (Step 2) on general considerations for patient preference studies was issued for consultation around the end of 2025 (raps.org). This draft (under ICH Efficacy umbrella) outlines how patient preference information can be systematically used – including study design principles, recommended conduct and analysis methods, and submission format for preference studies intended to accompany clinical trial results in regulatory filings. The goal is to ensure patient preference data affecting trial outcomes or benefit-risk assessments are collected with methodological rigor and are interpretable for regulators. (This guideline remains in draft, with global consultation ongoing into 2026.) 

• ICH E20 (Adaptive Clinical Trials) – Ongoing Draft – (For context, ICH’s draft E20 guideline on adaptive trial designs reached Step 2 in mid-2025 and remained under consultation through the end of 2025 (gmp-compliance.org). Although not a new December 2025 release, it is an important draft in progress, emphasizing principles to ensure that adaptive trial methods yield robust and interpretable results. Finalization is expected after stakeholder feedback is integrated.)